A Phase 1b, Open-label, Dose-finding Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of Avelumab (MSB0010718C) In Combination With Axitinib (AG-013736) In Patients With Previously Untreated Advanced Renal Cell Cancer

Trial Profile

A Phase 1b, Open-label, Dose-finding Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of Avelumab (MSB0010718C) In Combination With Axitinib (AG-013736) In Patients With Previously Untreated Advanced Renal Cell Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Avelumab (Primary) ; Axitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions
  • Acronyms JAVELIN Renal 100
  • Sponsors Pfizer
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 02 Jun 2017 Results (data cut of: Dec 30, 2016) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 02 Jun 2017 Status changed to active, no longer recruiting as per result presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top